metronidazole has been researched along with Vaginal Discharge in 20 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Vaginal Discharge: A common gynecologic disorder characterized by an abnormal, nonbloody discharge from the genital tract.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Significant reduction of malodorous vaginal discharge (whiff test) and lowest recurrence of BV were noted in the metronidazole plus lactic acid gel arm." | 5.12 | Metronidazole with Lactacyd vaginal gel in bacterial vaginosis. ( Co, JT; Dancel, LA; Decena, DC; Lelis, MA; Manalastas, RM; Padolina, CS; Palaypayon, EP; Sison, JM, 2006) |
| "A randomized controlled effectiveness trial compared single-dose tinidazole plus fluconazole (TF) with treatment for 7 days with metronidazole plus 3 days of treatment with vaginal clotrimazole (MC) among 1570 women presenting with vaginal discharge at primary health care institutions in Ghana, Guinea, Mali and Togo." | 5.12 | The syndromic management of vaginal discharge using single-dose treatments: a randomized controlled trial in West Africa. ( Agyarko-Poku, T; Asamoah-Adu, C; Deslandes, S; Diakité, S; Frost, E; Khonde, N; Labbé, AC; Pépin, J; Sobela, F; Sylla, M, 2006) |
| " The overall number of treatment-emergent adverse events (TEAEs) was 95 (29." | 2.87 | A Phase 3, Multicenter, Prospective, Open-Label Study to Evaluate the Safety of a Single Dose of Secnidazole 2 g for the Treatment of Women and Postmenarchal Adolescent Girls with Bacterial Vaginosis. ( Chavoustie, SE; Gersten, JK; Samuel, MJ; Schwebke, JR, 2018) |
| " Adverse events considered by the investigator to be related to study drug occurred in only 20." | 2.84 | A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. ( Koltun, W; Morgan, FG; Nyirjesy, P; Schwebke, JR, 2017) |
| " No serious adverse events were reported, and incidence was similar across treatment groups." | 2.80 | A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis. ( Beelen, AP; Marrazzo, J; Schwebke, JR; Sobel, JD, 2015) |
| "Half of all women with bacterial vaginosis are free of symptoms, and treatment of these women is controversial." | 2.69 | Asymptomatic bacterial vaginosis: response to therapy. ( Schwebke, JR, 2000) |
| "Most patients with vulvovaginal candidiasis are diagnosed by the presence of vulvar inflammation plus vaginal discharge or with microscopic examination of vaginal secretions in 10 percent potassium hydroxide solution." | 2.47 | Vaginitis. ( Gibson, MV; Hainer, BL, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ayinde, O | 1 |
| Ross, JD | 1 |
| Sim, M | 1 |
| Logan, S | 1 |
| Goh, LH | 1 |
| Zwittink, RD | 1 |
| van den Munckhof, EHA | 1 |
| Leverstein-van Hall, MA | 1 |
| Boers, K | 1 |
| Molijn, A | 1 |
| Knetsch, CW | 1 |
| Kuijper, EJ | 1 |
| Schwebke, JR | 4 |
| Morgan, FG | 1 |
| Koltun, W | 1 |
| Nyirjesy, P | 1 |
| Elwakil, HS | 1 |
| Tawfik, RA | 1 |
| Alam-Eldin, YH | 1 |
| Nassar, DA | 1 |
| Chavoustie, SE | 1 |
| Gersten, JK | 1 |
| Samuel, MJ | 1 |
| Marrazzo, J | 1 |
| Beelen, AP | 1 |
| Sobel, JD | 1 |
| Ertabaklar, H | 1 |
| Yaman Karadam, S | 1 |
| Malatyalı, E | 1 |
| Ertuğ, S | 1 |
| Hainer, BL | 1 |
| Gibson, MV | 1 |
| Moraes, ME | 1 |
| Cunha, GH | 1 |
| Bezerra, MM | 1 |
| Fechine, FV | 1 |
| Pontes, AV | 1 |
| Andrade, WS | 1 |
| Frota Bezerra, FA | 1 |
| Moraes, MO | 1 |
| Cavalcanti, PP | 1 |
| Ressel, GW | 1 |
| French, L | 1 |
| Horton, J | 1 |
| Matousek, M | 1 |
| Sheeley, A | 1 |
| Decena, DC | 1 |
| Co, JT | 1 |
| Manalastas, RM | 1 |
| Palaypayon, EP | 1 |
| Padolina, CS | 1 |
| Sison, JM | 1 |
| Dancel, LA | 1 |
| Lelis, MA | 1 |
| Anukam, KC | 1 |
| Osazuwa, E | 1 |
| Osemene, GI | 1 |
| Ehigiagbe, F | 1 |
| Bruce, AW | 1 |
| Reid, G | 1 |
| Pépin, J | 1 |
| Sobela, F | 1 |
| Khonde, N | 1 |
| Agyarko-Poku, T | 1 |
| Diakité, S | 1 |
| Deslandes, S | 1 |
| Labbé, AC | 1 |
| Sylla, M | 1 |
| Asamoah-Adu, C | 1 |
| Frost, E | 1 |
| Winceslaus, SJ | 1 |
| Calver, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Impact of Using Maternity Napkins on the Incidence of Vaginal Infections in the Post-partum Period: A Randomized Controlled Trial[NCT05806879] | 350 participants (Anticipated) | Interventional | 2023-06-30 | Not yet recruiting | |||
| Real-world Performance and Safety of Cerviron® Medical Device in the Treatment of Various Types of Vaginitis[NCT05652959] | 111 participants (Actual) | Observational | 2021-05-20 | Completed | |||
| A Randomised Controlled Trial of Single Dose Tinidazole+Fluconazole Versus Longer Courses of Metronidazole+Clotrimazole in the Management of West African Women With Vaginal Discharge[NCT00313131] | Phase 3 | 1,524 participants | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for metronidazole and Vaginal Discharge
| Article | Year |
|---|---|
Vaginitis.
Topics: Administration, Intravaginal; Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; An | 2011 |
Vaginitis.
Topics: Administration, Intravaginal; Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; An | 2011 |
Vaginitis.
Topics: Administration, Intravaginal; Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; An | 2011 |
Vaginitis.
Topics: Administration, Intravaginal; Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; An | 2011 |
Abnormal vaginal discharge: what does and does not work in treating underlying causes.
Topics: Anti-Bacterial Agents; Antifungal Agents; Candidiasis, Vulvovaginal; Clindamycin; Female; Humans; Me | 2004 |
Sorting out common causes of abnormal vaginal discharge.
Topics: Anti-Infective Agents; Female; Humans; Hydrogen-Ion Concentration; Metronidazole; Patient Education | 2004 |
9 trials available for metronidazole and Vaginal Discharge
| Article | Year |
|---|---|
A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Candidiasis, Vulvovaginal; Diarrhea; | 2017 |
A Phase 3, Multicenter, Prospective, Open-Label Study to Evaluate the Safety of a Single Dose of Secnidazole 2 g for the Treatment of Women and Postmenarchal Adolescent Girls with Bacterial Vaginosis.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Female; Humans; Metronidazole; Prospe | 2018 |
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis.
Topics: Administration, Intravaginal; Adult; Anti-Bacterial Agents; Double-Blind Method; Female; Humans; Met | 2015 |
Efficacy of the Mentha crispa in the treatment of women with Trichomonas vaginalis infection.
Topics: Adult; Antitrichomonal Agents; Double-Blind Method; Dyspareunia; Dysuria; Female; Humans; Male; Ment | 2012 |
Metronidazole with Lactacyd vaginal gel in bacterial vaginosis.
Topics: Adult; Anti-Infective Agents; Drug Combinations; Female; Humans; Hydrogen-Ion Concentration; Immune | 2006 |
Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis.
Topics: Administration, Intravaginal; Adult; Anti-Bacterial Agents; Female; Humans; Lactobacillus; Metronida | 2006 |
The syndromic management of vaginal discharge using single-dose treatments: a randomized controlled trial in West Africa.
Topics: Adolescent; Adult; Africa, Western; Animals; Anti-Infective Agents; Antifungal Agents; Antitrichomon | 2006 |
Recurrent bacterial vaginosis--an old approach to a new problem.
Topics: Administration, Intravaginal; Anti-Infective Agents, Local; Antitrichomonal Agents; Female; Humans; | 1996 |
Asymptomatic bacterial vaginosis: response to therapy.
Topics: Adult; Anti-Infective Agents; Double-Blind Method; Female; Gels; Humans; Metronidazole; Odorants; Tr | 2000 |
8 other studies available for metronidazole and Vaginal Discharge
| Article | Year |
|---|---|
The association between symptom or microscopy based diagnosis of bacterial vaginosis (BV) and response to treatment in women with recurrent BV.
Topics: Female; Humans; Metronidazole; Microscopy; Vagina; Vaginal Discharge; Vaginosis, Bacterial | 2023 |
Vaginal discharge: evaluation and management in primary care.
Topics: Anti-Infective Agents; Antifungal Agents; Female; Fluconazole; Humans; Metronidazole; Primary Health | 2020 |
The vaginal microbiota in the course of bacterial vaginosis treatment.
Topics: Adult; Anti-Bacterial Agents; Bacteria; Clindamycin; Female; Host Specificity; Humans; Metronidazole | 2021 |
The effect of iron on metronidazole activity against Trichomonas vaginalis in vitro.
Topics: Adult; Aerobiosis; Anaerobiosis; Antiprotozoal Agents; Drug Interactions; Female; Ferredoxins; Ferro | 2017 |
[Investigation of in vitro metronidazole resistance in the clinical isolates of Trichomonas vaginalis].
Topics: Anaerobiosis; Antiprotozoal Agents; Drug Resistance; Female; Humans; Metronidazole; Microbial Sensit | 2016 |
CDC releases 2002 guidelines for treating STDs: Part I. Diseases characterized by vaginal discharge and PID.
Topics: Anti-Infective Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Metronidazole; Pelvic | 2002 |
National guideline for the management of bacterial vaginosis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases).
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Clindamycin; Drug Administration Schedule; Fema | 1999 |
National guideline for the management of Trichomonas vaginalis. Clinical Effectiveness Group (Association for Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases).
Topics: Adult; Animals; Antitrichomonal Agents; Breast Feeding; Child, Preschool; Female; Humans; Infectious | 1999 |